128 related articles for article (PubMed ID: 10737756)
1. Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
Hale JJ; Mills SG; MacCoss M; Dorn CP; Finke PE; Budhu RJ; Reamer RA; Huskey SE; Luffer-Atlas D; Dean BJ; McGowan EM; Feeney WP; Chiu SH; Cascieri MA; Chicchi GG; Kurtz MM; Sadowski S; Ber E; Tattersall FD; Rupniak NM; Williams AR; Rycroft W; Hargreaves R; Metzger JM; MacIntyre DE
J Med Chem; 2000 Mar; 43(6):1234-41. PubMed ID: 10737756
[TBL] [Abstract][Full Text] [Related]
2. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.
Tattersall FD; Rycroft W; Cumberbatch M; Mason G; Tye S; Williamson DJ; Hale JJ; Mills SG; Finke PE; MacCoss M; Sadowski S; Ber E; Cascieri M; Hill RG; MacIntyre DE; Hargreaves RJ
Neuropharmacology; 2000 Feb; 39(4):652-63. PubMed ID: 10728886
[TBL] [Abstract][Full Text] [Related]
3. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
Hale JJ; Mills SG; MacCoss M; Finke PE; Cascieri MA; Sadowski S; Ber E; Chicchi GG; Kurtz M; Metzger J; Eiermann G; Tsou NN; Tattersall FD; Rupniak NM; Williams AR; Rycroft W; Hargreaves R; MacIntyre DE
J Med Chem; 1998 Nov; 41(23):4607-14. PubMed ID: 9804700
[TBL] [Abstract][Full Text] [Related]
4. An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration.
Harrison T; Owens AP; Williams BJ; Swain CJ; Williams A; Carlson EJ; Rycroft W; Tattersall FD; Cascieri MA; Chicchi GG; Sadowski S; Rupniak NM; Hargreaves RJ
J Med Chem; 2001 Nov; 44(24):4296-9. PubMed ID: 11708932
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
Watanabe Y; Asai H; Ishii T; Kiuchi S; Okamoto M; Taniguchi H; Nagasaki M; Saito A
J Pharmacol Sci; 2008 Jan; 106(1):121-7. PubMed ID: 18187929
[TBL] [Abstract][Full Text] [Related]
6. Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret.
Tsuchiya M; Fujiwara Y; Kanai Y; Mizutani M; Shimada K; Suga O; Ueda S; Watson JW; Nagahisa A
Pharmacology; 2002 Nov; 66(3):144-52. PubMed ID: 12372904
[TBL] [Abstract][Full Text] [Related]
7. The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret.
Singh L; Field MJ; Hughes J; Kuo BS; Suman-Chauhan N; Tuladhar BR; Wright DS; Naylor RJ
Eur J Pharmacol; 1997 Feb; 321(2):209-16. PubMed ID: 9063690
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three preclinical models for nausea and vomiting assessment.
Goineau S; Castagné V
J Pharmacol Toxicol Methods; 2016; 82():45-53. PubMed ID: 27477617
[TBL] [Abstract][Full Text] [Related]
9. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
Duffy RA; Morgan C; Naylor R; Higgins GA; Varty GB; Lachowicz JE; Parker EM
Pharmacol Biochem Behav; 2012 Jul; 102(1):95-100. PubMed ID: 22497992
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists.
Rupniak NM; Tattersall FD; Williams AR; Rycroft W; Carlson EJ; Cascieri MA; Sadowski S; Ber E; Hale JJ; Mills SG; MacCoss M; Seward E; Huscroft I; Owen S; Swain CJ; Hill RG; Hargreaves RJ
Eur J Pharmacol; 1997 May; 326(2-3):201-9. PubMed ID: 9196273
[TBL] [Abstract][Full Text] [Related]
11. Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
Youssefyeh RD; Campbell HF; Airey JE; Klein S; Schnapper M; Powers M; Woodward R; Rodriguez W; Golec S; Studt W
J Med Chem; 1992 Mar; 35(5):903-11. PubMed ID: 1548679
[TBL] [Abstract][Full Text] [Related]
12. Substance P receptor antagonist I: conversion of phosphoramidate prodrug after i.v. administration to rats and dogs.
Huskey SE; Luffer-Atlas D; Dean BJ; McGowan EM; Feeney WP; Chiu SH
Drug Metab Dispos; 1999 Nov; 27(11):1367-73. PubMed ID: 10534323
[TBL] [Abstract][Full Text] [Related]
13. Antiemetic effects of a potent and selective neurokinin-1 receptor antagonist, FK886, on cisplatin- and apomorphine-induced emesis in dogs.
Furukawa TY; Nakayama H; Kikuchi A; Imazumi K; Yamakuni H; Sogabe H; Yamasaki S; Takeshita K; Matsuo M; Manda T; Uchida W
Biol Pharm Bull; 2013; 36(6):974-9. PubMed ID: 23727919
[TBL] [Abstract][Full Text] [Related]
14. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040.
Gardner CJ; Twissell DJ; Dale TJ; Gale JD; Jordan CC; Kilpatrick GJ; Bountra C; Ward P
Br J Pharmacol; 1995 Dec; 116(8):3158-63. PubMed ID: 8719790
[TBL] [Abstract][Full Text] [Related]
15. Automated analysis of delayed emesis in the telemetered ferret: detection of synergistic effects of aprepitant and ondansetron.
Goineau S; Guillaume P; Barrais L; Castagné V
Fundam Clin Pharmacol; 2014 Dec; 28(6):643-51. PubMed ID: 24750138
[TBL] [Abstract][Full Text] [Related]
16. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists.
Duffy RA; Varty GB; Morgan CA; Lachowicz JE
J Pharmacol Exp Ther; 2002 May; 301(2):536-42. PubMed ID: 11961054
[TBL] [Abstract][Full Text] [Related]
17. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
Navari RM; Reinhardt RR; Gralla RJ; Kris MG; Hesketh PJ; Khojasteh A; Kindler H; Grote TH; Pendergrass K; Grunberg SM; Carides AD; Gertz BJ
N Engl J Med; 1999 Jan; 340(3):190-5. PubMed ID: 9917226
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
[TBL] [Abstract][Full Text] [Related]
19. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
[TBL] [Abstract][Full Text] [Related]
20. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists.
Sauer R; Maurinsh J; Reith U; Fülle F; Klotz KN; Müller CE
J Med Chem; 2000 Feb; 43(3):440-8. PubMed ID: 10669571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
